# The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

> **NCT01697306** · PHASE2 · COMPLETED · sponsor: **A.O.U. Città della Salute e della Scienza** · enrollment: 120 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Gemcitabine 2 g
- **DRUG:** BCG Vaccine

## Key facts

- **NCT ID:** NCT01697306
- **Lead sponsor:** A.O.U. Città della Salute e della Scienza
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2011-03
- **Final completion:** 2012-05
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-01-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01697306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01697306, "The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01697306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*